Evidence for continuous stimulation of interleukin-6 production in Crohn's disease
- PMID: 1370661
- DOI: 10.1016/0016-5085(92)90098-j
Evidence for continuous stimulation of interleukin-6 production in Crohn's disease
Abstract
Increased serum concentrations of acute-phase proteins can be found in active inflammatory bowel disease. Because interleukin 6 (IL-6) is one of the main mediators of acute-phase protein synthesis by the liver, the serum concentrations of IL-6 and the acute-phase proteins C-reactive protein, alpha 1-antitrypsin, and alpha 1-acid glycoprotein were determined in 70 patients with Crohn's disease (CD) and 23 patients with ulcerative colitis (UC). Disease activities were determined by established clinical activity indices. Serum IL-6 concentrations were significantly (P less than 0.005) increased in patients with CD (mean +/- SEM, 6.8 +/- 0.9 U/mL) compared with patients with UC (mean, less than 4 U/mL) and healthy controls (mean, less than 4 U/mL). Of patients with CD, 68.5% had serum IL-6 concentrations of greater than or equal to 4 U/mL, compared with 21.7% of patients with UC and 0% of healthy controls. There was a tendency toward higher serum IL-6 concentrations in patients with active CD than in patients with inactive disease. However, these differences were not statistically significant. There was no correlation between IL-6 serum concentrations and clinical activity indices, possibly because of the short circulatory lifetime and rapid hepatic clearance of IL-6 from the portal venous blood. In contrast to serum IL-6, acute-phase proteins, which have a longer circulatory lifetime, were significantly correlated with clinical activity indices. Only the follow-up of individual patients with initially highly active disease showed a further increase in IL-6 levels during acute exacerbations of the inflammatory process. The results show that most patients with even moderately active CD have significantly increased serum concentrations of IL-6, most probably reflecting a continuous stimulation of IL-6-producing cells.
Comment in
-
Interleukin-6 production in Crohn's disease.Gastroenterology. 1992 Sep;103(3):1120-1. doi: 10.1016/0016-5085(92)90072-7. Gastroenterology. 1992. PMID: 1499921 No abstract available.
Similar articles
-
Interrelations between interleukin-6, interleukin-1 beta, plasma C-reactive protein values, and in vitro C-reactive protein generation in patients with inflammatory bowel disease.Gut. 1994 Jan;35(1):77-83. doi: 10.1136/gut.35.1.77. Gut. 1994. PMID: 8307455 Free PMC article.
-
Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis.Hepatogastroenterology. 1997 Jan-Feb;44(13):90-107. Hepatogastroenterology. 1997. PMID: 9058126
-
Circulating antiinflammatory cytokine IL-10 in patients with inflammatory bowel disease (IBD).Clin Exp Immunol. 1995 Jun;100(3):452-6. doi: 10.1111/j.1365-2249.1995.tb03721.x. Clin Exp Immunol. 1995. PMID: 7774055 Free PMC article.
-
Serum interleukin-6 is related to disease activity but not disease specificity in inflammatory bowel disease.J Clin Gastroenterol. 1995 Mar;20(2):123-6. doi: 10.1097/00004836-199503000-00010. J Clin Gastroenterol. 1995. PMID: 7769191
-
Soluble interleukin-2 receptor, interleukin-6 and interleukin-1 beta in patients with Crohn's disease and ulcerative colitis: preoperative levels and postoperative changes of serum concentrations.Digestion. 1992;51(1):51-9. doi: 10.1159/000200875. Digestion. 1992. PMID: 1639222
Cited by
-
Increased expression of long pentraxin PTX3 in inflammatory bowel diseases.Dig Dis Sci. 2008 Jul;53(7):1910-6. doi: 10.1007/s10620-007-0075-z. Epub 2007 Nov 8. Dig Dis Sci. 2008. PMID: 17990107
-
Metabolic bone disease and parenteral nutrition.Curr Gastroenterol Rep. 2004 Aug;6(4):335-41. doi: 10.1007/s11894-004-0087-1. Curr Gastroenterol Rep. 2004. PMID: 15245704 Review.
-
Olmesartan medoxomil self-microemulsifying drug delivery system reverses apoptosis and improves cell adhesion in trinitrobenzene sulfonic acid-induced colitis in rats.Drug Deliv. 2022 Dec;29(1):2017-2028. doi: 10.1080/10717544.2022.2086939. Drug Deliv. 2022. PMID: 35766160 Free PMC article.
-
Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling.MAbs. 2014 May-Jun;6(3):774-82. doi: 10.4161/mabs.28612. Epub 2014 Apr 2. MAbs. 2014. PMID: 24670876 Free PMC article.
-
Interrelations between interleukin-6, interleukin-1 beta, plasma C-reactive protein values, and in vitro C-reactive protein generation in patients with inflammatory bowel disease.Gut. 1994 Jan;35(1):77-83. doi: 10.1136/gut.35.1.77. Gut. 1994. PMID: 8307455 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials